"Peptides for arthritis" is searched about 2,000 times a month in the US, and the answers on page one mostly mean one thing by it: BPC-157, TB-500 and the other injectables sold for "joint repair". Those compounds are the subject of our joint-pain page, which reads their one human joint study in the original.
This page asks the question the other way round. Not "what do the joint peptides do for arthritis" — none of them has a trial in people with arthritis in the searches below — but which peptides have actually been put through a trial in people with arthritis, and what happened. That list exists, it is longer than most readers expect, and almost none of it is on sale.
This page is research journalism. It reports what trials and registries recorded, and contains no treatment or usage guidance; arthritis is a condition for a rheumatologist or GP to manage.
The count, done on 17 November 2026
The peptides sold for joints.
- ClinicalTrials.gov: BPC-157 under any arthritis condition, 0 studies. GHK-Cu or "copper peptide" under arthritis, 0. Thymosin beta-4 or TB-500 under arthritis, 1 — and it is a nine-patient trial of thymosin beta-4 eye drops for severe dry eye (NCT01393132), which the search matched on a listed condition, not a joint study.
- PubMed: BPC-157 crossed with arthritis, 5 records. One is a 1997 study in rats with adjuvant-induced arthritis (PMID 9403784); three are review articles by the same research group on BPC-157 in the gut and against damage from anti-inflammatory drugs; the fifth is the 2021 knee-pain chart review read on the joint-pain page. None is a study of people with arthritis.
The peptides tested in arthritis are a different set, and the ledger below is built from PubMed's randomised-trial filter and the registry, each record read at abstract level.
Osteoarthritis
| Peptide (type) | Trial | People | What was measured | Result |
|---|---|---|---|---|
| Oral salmon calcitonin (peptide hormone) | Two phase 3 trials, 24 months | 1,176 and 1,030, knee OA | Joint-space width on X-ray; WOMAC | No effect on joint-space narrowing in either; a WOMAC difference in one could not be claimed under its testing order |
| Semaglutide 2.4 mg weekly (GLP-1 drug) | STEP 9, 68 weeks | 407, obesity + knee OA | Weight; WOMAC pain | Pain −41.7 v −27.5 points; weight −13.7% v −3.2% |
| Liraglutide 3 mg daily (GLP-1 drug) | 52 weeks, after an 8-week diet | 156 randomised, knee OA, BMI ≥27 | Weight; KOOS pain | Weight 3.9 kg lower than placebo; no pain difference (P = 0.71) |
| TPX-100 (injected peptide candidate) | Phase 2, one knee drug, other knee placebo | 104 randomised, 78 analysed by MRI | Bone shape on MRI (B-score); cartilage | Less bone-shape change at 6 and 12 months; analysis described as retrospective |
| Sprifermin (recombinant FGF-18 — a protein) | FORWARD, 2 years | 549, knee OA | Cartilage thickness on MRI; WOMAC | +0.05 mm at the top dose; no WOMAC difference |
Oral calcitonin is the clearest result, and it is a negative one. The two trials randomised 2,206 patients with painful knee osteoarthritis to an oral salmon calcitonin tablet at 0.8 mg twice a day or placebo for two years. At 24 months "there was no statistically significant treatment effect on joint space narrowing" in either trial; one trial showed effects on WOMAC and on bone and cartilage markers, "but due to the hierarchical testing procedure the treatment effect was not claimed statistically significant". The authors, most of them from the sponsor Nordic Bioscience, concluded that the formulation "did not provide reproducible clinical benefits" (Karsdal et al., Osteoarthritis Cartilage 2015, PMID 25582279). The registry lists the second trial (NCT00704847) as terminated. The line is not closed: a calcitonin-search result on the same registry, KBP-336, is in a 600-patient phase 2 trial in people with obesity and osteoarthritis, recruiting on 17 November 2026 (NCT06833749).
GLP-1 drugs are the one peptide class with a large positive arthritis trial, and the effect travels with weight. STEP 9 enrolled 407 adults with obesity and moderate knee osteoarthritis — mean age 56, mean BMI 40.3, 81.6% women — and randomised them 2:1 to semaglutide 2.4 mg weekly or placebo, both with diet and activity counselling. At 68 weeks WOMAC pain had fallen 41.7 points against 27.5, and body weight 13.7% against 3.2%. Discontinuation for adverse events was 6.7% against 3.0%, mostly gastrointestinal. The trial was funded by Novo Nordisk (Bliddal et al., NEJM 2024, PMID 39476339).
The smaller Danish trial is the necessary counterweight. Patients with knee osteoarthritis first lost weight on an eight-week diet — and their pain fell during it — and those who had lost more than 5% were then randomised to liraglutide 3 mg a day or placebo for a year. Liraglutide held 3.9 kg more weight off, and knee pain did not differ: 0.4 against −0.6 KOOS points, P = 0.71 (Gudbergsen et al., Am J Clin Nutr 2021, PMID 33471039; the abstract's objective line reads "30 mg/d", its methods "3 mg/d"). Put together, the two trials fit the reading that a GLP-1 drug helps knee pain through large weight loss rather than through the joint. A tirzepatide trial in obesity and knee osteoarthritis, 352 patients at the University of Melbourne, was listed as active and not recruiting on the same date (NCT06191848). The weight-loss-drug side of this question is GLP1Ledger's subject, on its GLP-1 and arthritis page.
The two injected cartilage candidates are earlier and smaller. TPX-100 was injected into one knee and placebo into the other in 104 people with cartilage defects in both knees; of the subjects with usable MRI, the TPX-100 knees showed less change in femoral bone shape at 6 and 12 months. The paper is by the developer, OrthoTrophix, describes the analysis as retrospective, and refers to earlier WOMAC function results rather than reporting them (McGuire et al., Arthritis Res Ther 2021, PMID 34535197). The trial's registry record (NCT01925261, 120 enrolled, completed) has no results posted; a 270-patient phase 2 follow-on was listed as active and not recruiting on 17 November 2026 (NCT06865079).
Sprifermin is included because it is often grouped with "peptide" cartilage treatments, though it is a recombinant protein. In FORWARD, 549 patients received knee injections at one of four regimens or placebo; at two years the 100 µg every-six-months group had 0.05 mm more femorotibial cartilage than placebo (95% CI 0.03 to 0.07 mm), and no regimen differed from placebo on WOMAC. The authors called the cartilage gain "of uncertain clinical importance" (Hochberg et al., JAMA 2019, PMID 31593273).
Rheumatoid arthritis
Rheumatoid arthritis is an autoimmune disease, and the peptides tested in it are designed to retrain the immune response rather than to repair a joint.
| Peptide immunotherapy | Trial | People | Result as reported |
|---|---|---|---|
| IR501, three T-cell-receptor peptides | Phase 2, placebo-controlled, 4 injections over 20 weeks | 99 | Safe; the 90 µg group significantly better than control on ACR20 at week 20 in intention-to-treat analysis; trends at week 24 |
| DR4/1 "shared epitope" peptide | Dose-escalating, placebo-controlled | 53 (44 completed) | Safe, no broad immune suppression; no dose response; "trends toward improvement" in one dosing group |
| dnaJP1, oral, 25 mg daily for 6 months | Pilot phase 2, placebo-controlled | 160 | Safe; primary ACR20 difference significant only in post hoc analysis |
| DEN-181, collagen peptide in liposomes | Phase 1, single dose, placebo-controlled | 17 | Well tolerated; changes in autoreactive T cells; clinical findings exploratory |
Sources, in order: Moreland et al., Arthritis Rheum 1998, PMID 9811045; St Clair et al., J Rheumatol 2000, PMID 10955324; Koffeman et al., Arthritis Rheum 2009, PMID 19877047; Sonigra et al., JCI Insight 2022, PMID 36278483.
Twenty-four years separate the first and last of these, and the pattern holds across them: each trial established safety, and none produced a clean, pre-specified efficacy result. The 2022 trial dosed patients who were already on methotrexate, which is the standard of care these approaches would have to add to. The searches for this page found no later-phase trial reported for any of the four.
Collagen peptides, briefly
Collagen peptides are the one peptide supplement with a real trial base in osteoarthritis: PubMed's randomised-trial filter returned 52 records for collagen peptide crossed with osteoarthritis on 17 November 2026. The results are modest, often industry-funded and include nulls; the trials are tabled one by one on collagen for joints, and what the same ingredient does elsewhere is on collagen peptides benefits.
What the ledger shows
- The compounds most marketed for joints are the ones never tested in arthritis. BPC-157 has a rat study; TB-500 and GHK-Cu have no arthritis study in the registry at all.
- The peptides that were tested mostly failed or stalled. Oral calcitonin failed twice at phase 3; the rheumatoid-arthritis vaccines stopped at trends; the cartilage candidates' headline results are imaging changes, and FORWARD found no WOMAC difference.
- The one large positive result is a weight-loss drug, and the trial that separated weight loss from the drug found no pain benefit.
- Sport status is a separate question. What WADA and the NCAA list for the injectables is on peptides and drug testing.
Limits of this page
All counts are from searches run on 17 November 2026 and will change; the search terms are given above so they can be re-run. Trials were read as abstracts, not full texts. The registry searches matched on condition and intervention fields and can miss studies that use other names. The page does not survey what clinics or vendors claim for arthritis. Nothing here addresses whether any treatment suits a particular person; that is for a clinician.
Sources
- ClinicalTrials.gov API v2, searched 2026-11-17: condition "arthritis" with intervention BPC-157 (0), TB-500 OR thymosin beta 4 (1, NCT01393132), GHK-Cu OR copper peptide (0); condition "osteoarthritis" with calcitonin (6, incl. NCT00486434, NCT00704847, NCT06833749), TPX-100 (4, incl. NCT01925261, NCT06865079), semaglutide OR tirzepatide OR liraglutide (15, incl. NCT05064735, NCT02905864, NCT06191848).
- PubMed E-utilities, searched 2026-11-17: "BPC-157 AND arthritis" (5); "collagen peptide AND osteoarthritis AND randomized controlled trial[pt]" (52); "salmon calcitonin AND osteoarthritis AND randomized controlled trial[pt]" (9).
- Karsdal MA et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthritis Cartilage 2015;23(4):532–43. PMID 25582279
- Bliddal H et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med 2024;391(17):1573–83. PMID 39476339
- Gudbergsen H et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr 2021. PMID 33471039
- McGuire D et al. Study TPX-100-5: intra-articular TPX-100 significantly delays pathological bone shape change and stabilizes cartilage in moderate to severe bilateral knee OA. Arthritis Res Ther 2021;23:242. PMID 34535197
- Hochberg MC et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. JAMA 2019;322(14):1360–70. PMID 31593273
- Moreland LW et al. T cell receptor peptide vaccination in rheumatoid arthritis. Arthritis Rheum 1998;41(11):1919–29. PMID 9811045
- St Clair EW et al. Treatment of rheumatoid arthritis with a DR4/1 peptide. J Rheumatol 2000;27(8):1855–63. PMID 10955324
- Koffeman EC et al. Epitope-specific immunotherapy of rheumatoid arthritis. Arthritis Rheum 2009;60(11):3207–16. PMID 19877047
- Sonigra A et al. Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis. JCI Insight 2022;7(20):e160964. PMID 36278483
- Sikiric P et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol Paris 1997. PMID 9403784
